Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab dose-ranging study in active psoriatic arthritis
2015-003625-34Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Risankizumab dose-ranging with Placebo (2 arms). Primary endpoint: ACR20 response at Week 16. Started Feb 2016; status: completed.
02
Drugs
risankizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2015-003625-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003625-34.